Effects of etomidate on complications related to intubation and on mortality in septic shock patients treated with hydrocortisone: a propensity score analysis
© Jung et al.; licensee BioMed Central Ltd. 2012
Received: 28 May 2012
Accepted: 12 November 2012
Published: 21 November 2012
Endotracheal intubation in the ICU is associated with a high incidence of complications. Etomidate use is debated in septic shock because it increases the risk of critical illness-related corticosteroid insufficiency, which may impact outcome. We hypothesized that hydrocortisone, administered in all septic shock cases in our ICU, may counteract some negative effects of etomidate.
The aim of our study was to compare septic shock patients who received etomidate versus another induction drug both for short-term safety and for long-term outcomes.
A single-center observational study was carried out in septic shock patients, treated with hydrocortisone and intubated within the first 48 hours of septic shock. Co-primary end points were life-threatening complications incidence occurring within the first hour after intubation and mortality during the ICU stay. Statistical analyses included unmatched and matched cohorts using a propensity score analysis. P < 0.05 was considered significant.
Sixty patients in the etomidate cohort and 42 patients in the non-etomidate cohort were included. Critical illness-related corticosteroid insufficiency was 79% in the etomidate cohort and 52% in the non-etomidate cohort (P = 0.01). After intubation, life-threatening complications occurred in 36% of the patients whatever the cohort. After adjustment with propensity score analysis, etomidate was a protective factor for death in the ICU both in unmatched (hazard ratio, 0.33 (0.15 to 0.75); P < 0.01)) and matched cohorts (hazard ratio, 0.33 (0.112 to 0.988); P = 0.04).
In septic shock patients treated with hydrocortisone, etomidate did not decrease life-threatening complications following intubation, but when associated with hydrocortisone it also did not impair outcome.
Endotracheal intubation, one of the most commonly performed procedures in the ICU [1–3], is associated with a high incidence of early onset life-threatening complications (25 to 39%) because of the precarious hemodynamic and respiratory status of those patients [1, 2, 4]. To limit intubation-related life-threatening complications, bundle therapy including hemodynamically well-tolerated anesthetics such as etomidate has been suggested in the ICU [1, 5] and is widely used in prehospital or emergency room environments [6, 7]. In critically ill patients, the use of etomidate has been challenged because it inhibits adrenocortical steroid synthesis by reversibly blocking the 11β-hydroxylase enzyme action [8–10] for at least 24 hours after a single bolus [9, 11]. This inhibition is associated with a risk of reversible failure of the adrenal axis, which can lead to critical illness-related corticosteroid insufficiency (CIRCI) . Because CIRCI is associated with an increased mortality in septic shock patients [8, 13–15], etomidate use is controversial in this setting [16–19]. Moreover, some studies suggest a link between etomidate and poor outcome [11, 13, 14, 20–22] but others failed to confirm this link [6, 23–25].
To limit the potential consequences of etomidate on the adrenal axis, hydrocortisone administration may be of interest. To our knowledge, only one randomized controlled clinical trial, performed in nonseptic critically ill patients, failed to demonstrate any benefit to counteract etomidate's side effect using a short course (48 hours) of hydrocortisone treatment . In our ICU, the anesthesia bundle for intubation strongly recommends the use of a rapid sequence induction  and our septic shock bundle therapy includes hydrocortisone for all septic shock patients after a cosyntropin test as is frequently observed and suggested in France [15, 26, 27]. In our operating room, no local bundle is purposed, although ketamine and etomidate are suggested for critically ill patients. Because of its potential protective effect on intubation safety [3–5, 7], due to its cardiovascular properties, and its deleterious impact on adrenal gland physiology [8, 28], etomidate may have contrasting impact on the incidence of life-threatening complications occurring within 1 hour after intubation and on the long-term outcome in septic shock patients.
The present study was aimed at assessing the short-term safety and the long-term outcomes of septic patients treated with etomidate versus another induction drug for intubation. We designed the present propensity-score-driven study to evaluate, in septic shock patients, first the incidence of immediate life-threatening complications after intubation and second the long-term outcome according to the hypnotic used. The propensity score allowed us to match patients according to their probably to receive etomidate or not and to adjust for confounding factors in the present observational study.
Materials and methods
Study setting and patients
A cohort, observational study was performed in an adult ICU of a university hospital from June 2006 until December 2009. Data were extracted from prospective studies conducted in our ICU and previous databases [1, 2, 5, 15, 26]. The study was approved by the local ethics committee (Comité de Gestion et d'Organisation de l'Anesthésie Réanimation, Montpellier University Hospital) and, in accordance with French law, informed consent was waived. We adhered to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines .
Etomidate blocks cortisol synthesis primarily by inhibiting the activity of 11β-hydroxylase for at least 24 to 48 hours [10, 30]. Therefore, to describe the potential impact of etomidate on early and late outcome in septic shock patients, consecutive patients were eligible if they had received an induction agent for endotracheal intubation within the first 48 hours of septic shock onset. Patients were treated according to international guidelines for management of severe sepsis and septic shock  but all received hydrocortisone . Exclusion criteria included pregnancy, age < 18 years, moribund patients, immunosuppression, and long-term or short-term corticosteroid treatment within the past 4 weeks. A cosyntropin stimulation test with 250 μg cosyntropin was performed in all septic shock patients. A 50 mg intravenous bolus of hydrocortisone was then administered every 6 hours, beginning within the first 12 hours of septic shock, for at least 5 days, tapered and stopped in 5 days according to the reversal of shock. Patients were grouped as those having received etomidate for intubation (etomidate cohort) versus those subjects having received another hypnotic (non-etomidate cohort).
Septic shock was defined by evidence of infection and a systemic response to infection, in addition to systolic blood pressure < 90 mmHg, despite adequate fluid replacement, or a need for vasopressors for at least 1 hour, according to the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee criteria . Nonresponse to the cosyntropin stimulation test using an immunoradiology assay (SP2100; Beckmancoulter SAS, Roissy, France) was defined by a delta cortisol (60 minutes after 250 μg cosyntropin) < 9 μg/dl [15, 26, 28]. CIRCI was defined by a delta cortisol (60 minutes after 250 μg cosyntropin) < 9 μg/dl or a baseline plasma cortisol level < 10 μg/l .
A standardized data collection instrument and guidance tool was developed for data collection. Record review and data extraction were performed by a single investigator (NC) and regular meetings were conducted to address any problems encountered during the data collection phase according to the recommendations that have been published to minimize validity threats in chart review studies . Upon ICU admission, the baseline characteristics and the main variables obtained before intubation were recorded either by a nurse (from June 2006 to Jan 2009) or by computer-driven software plugged to the monitor, which recorded automatically all the variables.
At the time of intubation, clinical data including reason for intubation, interventions including sedative agent used, need for and doses of vasopressors were recorded. During the intubation procedure, drug administration and the difficulty to intubate rate (defined by three or more attempts at laryngoscopy to place the endotracheal tube into the trachea and/or > 10 minutes using conventional laryngoscopy and/or the need for another operator)  were documented. Within the first hour after intubation we recorded the short-term life-threatening complications that occurred, defined as previously reported [2, 5]: cardiac arrest, severe cardiovascular collapse (defined as systolic blood pressure < 65 mmHg recorded at least once and/or < 90 mmHg that lasted 30 minutes despite 500 to 1,000 ml fluid loading and/or requiring introduction of vasoactive support) and severe hypoxia (defined as a decrease in SpO2 level < 80% during attempts). Patients who already presented a cardiovascular collapse after fluid loading or who were severely hypoxemic (SpO2 < 80%) after preoxygenation by noninvasive positive-pressure ventilation were not considered to have had an intubation-related complication, but rather to have presented a life-threatening condition requiring an emergency endotracheal intubation.
During the ICU stay, we documented the results for basal plasma cortisol and that after the cosyntropin test, as well as total amounts and durations of hydrocortisone and vasopressor treatments from day 0 to day 5. Outcome data include the duration of shock, length of mechanical ventilation, nosocomial infection incidence, ICU and hospital lengths of stay, and day-28 mortality.
We had sufficient resources to review 102 patients in total. Descriptive data of quantitative variables were summarized as the mean ± standard deviation or median with interquartile range, according to the normality of the distribution, assessed with the Shapiro-Wilk test and compared with the Mann-Whitney or t test. Categorical data were expressed as the number and percentage and were compared with a chi-square analysis.
Using two statistical methods, we assessed the occurrence of short-term life-threatening complications and the long-term outcomes according to the administration of etomidate versus another hypnotic drug. First, unadjusted differences between patients receiving etomidate or not were compared using logistic regression after calibration with the Hosmer-Lemeshow wellness-of-fit test. Furthermore, long-term survival was assessed by a Cox regression in which we included all variables associated with P < 0.20 in the univariate analysis. A stepwise procedure then allowed the final multivariate model to be obtained.
Second, since patients were not randomly assigned to etomidate or other hypnotic in this observational study, we developed a propensity score using all variables associated with P < 0.20 in the univariate analysis. The propensity score is defined as a subject's probability of receiving a specific treatment (for example, etomidate) conditional on the observed covariates, and thus controls for selection bias in observational studies . For the coupling process, optimal one-to-one nearest neighbor matching was used. When needed, patients already matched were replaced by the closest one in the in the propensity score. P < 0.05 was considered significant. Statistical analysis was performed by an independent statistician (NM), with R software (version 2.10.1).
Baseline characteristics of the 102 studied patients
All patients (n= 102)
Etomidate cohort (n= 60)
Non-etomidate cohort (n= 42)
69 (58 to 75)
71 (62 to 72)
68 (56 to 73)
Body mass index (kg/m2)
25 (23 to 30)
25 (23 to 29)
26 (24 to 32)
SAPS II upon ICU admission
48 (40 to 63)
52 (42 to 65)
46 (34 to 58)
SOFA score upon ICU admission
8 (6 to 12)
10 (7 to 13)
8 (6 to 11)
Coronary artery disease
Congestive heart failure
Chronic obstructive pulmonary disease
Admitting diagnosis group
Time from infection diagnostic to surgery (hours)
8 (4 to 24)
8 (5 to 24)
8 (4 to 24)
Source of sepsis
Appropriateness of initial antibiotic therapy
Main variables obtained before intubation
Systolic blood pressure < 90 mmHg
SpO2 below 80%
2.5 (1.1 to 4.7)
2.5 (1.1 to 5.3)
2.3 (1.4 to 4.1)
Myorelaxant use to facilitate intubation
We first evaluated the association of hypnotics, intubation-related life-threatening complications and outcome in unmatched cohorts.
Intubation procedure and intubation-related complications
Comparison of main variables obtained before intubation according to occurrence of a short-term life-threatening complication
No life-threatening complications following intubation ( n = 65)
Life-threatening complications following intubation ( n = 37)
Odds ratio (95% CI)
SAPS II upon ICU admission
48 (37 to 59)
54 (44 to 70)
1.04 (0.99 to 1.08)
SOFA score upon ICU admission
8 (6 to 12)
8 (6 to 11)
Main variables obtained before intubation
2.6 (1.1 to 4.9)
2.2 (1.5 to 3.9)
0.11 (0.01 to 0.93)
Lowest systolic blood pressure recorded within 30 minutes before intubation (mmHg)
89 (80 to 120)
100 (90 to 122)
1.01 (0.99 to 1.03)
Drug used to facilitate intubation
0.60 (0.18 to 2.03)
Critical illness-related corticosteroid insufficiency and hydrocortisone treatment
Patients were compared according to the hypnotic they received to facilitate intubation. The cosyntropin test was performed within 24 hours after intubation in 85% of the patients, and after the first 24 hours in 15% of the population but always before the first dose of hydrocortisone. Hydrocortisone treatment was started 540 (300 to 1,125) minutes after intubation. The basal plasma cortisol concentration was significantly lower (19 (14 to 35) μg/dl versus 31 (17 to 45) μg/dl; P = 0.04) and the percentage of nonresponders to the cosyntropin stimulation test was significantly higher (79% vs. 52%; P = 0.01) in the etomidate cohort compared with the non-etomidate cohort. CIRCI was also significantly more frequently observed in the etomidate cohort compared with the non-etomidate cohort (79% vs. 59%; P = 0.04). In the etomidate cohort, the cumulative hydrocortisone dose was significantly higher (1,250 (650 to 1,650) mg vs. 750 (350 to 1,150) mg; P = 0.02) and the duration of treatment was significantly longer (168 (96 to 216) hours vs. 96 (48 to 162) hours; P = 0.01) than in the non-etomidate cohort.
Reversal of shock
Norepinephrine was administered within 12 hours after intubation in 100% of the patients without significant difference between cohorts. Patients in the etomidate cohort needed a higher cumulative dose of norepinephrine during their ICU stay compared with patients anesthetized with another hypnotic (95 (39 to 203) mg vs. 58 (30 to 97) mg from day 0 to day 5; P = 0.02). The duration of norepinephrine treatment was not different between cohorts (58 (37 to 94) hours in the etomidate cohort vs. 48 (25 to 81) hours in the non-etomidate cohort; P = 0.20).
ICU length of stay and complications
Long-term outcome according to the hypnotic used to facilitate intubation
Etomidate cohort (n= 60)
Non-etomidate cohort (n= 42)
Number of nosocomial infections
Urinary tract infections
Central venous catheter-related infections
Length of mechanical ventilation (days)
5 (2 to 14.8)
5 (1 to 7)
ICU length of stay (days)
12 (6 to 22)
9 (4 to 13)
Hospital length of stay (days)
32 (22 to 50)
29 (19 to 45)
Mortality at day 28
Comparison of main variables before intubation and cosyntropin test results between day-28 survivors and nonsurvivors
Survivors ( n = 66)
Nonsurvivors ( n = 36)
Hazard ratio (95% CI)
SAPS II upon ICU admission
45 (37 to 55)
60 (47 to 71)
1.04 (1.01 to 1.06)
SOFA score upon ICU admission
8 (5 to 11)
11 (8 to 13)
1.01 (0.89 to 1.16)
Main variables obtained before intubation
Drug used to facilitate intubation
0.33 (0.12 to 0.90)
Basal cortisol plasma level (μg/dl)
20 (14 to 40)
33 (19 to 49)
0.99 (0.96 to 1.03)
Cortisol plasma level after ACTH test (μg/dl)
31 (18 to 44)
35 (21 to 48)
Cosyntropin test responders
The results of our study show that, first, intubation in septic shock patients was associated with a 36% rate of short-term life-threatening complications and that this rate was independent of the hypnotic used to facilitate the procedure. Second, to our surprise, in unmatched cohorts and after matching using a propensity score analysis, the administration of a single dose of etomidate in septic shock patients treated with hydrocortisone was associated with a lower risk of day-28 mortality (Table 3).
Potential confounding factors of the study must be addressed. First, this study was a single-center observational study in which the hypnotic used for induction of anesthesia was not randomized. Second, this was a small study subject to unmeasured or residual confounding (for example, patient heterogeneity, heterogeneity for intubation indication, protocol deviation), which is a limitation. The propensity score, however, is a tool to increase the accuracy of results in cohort studies [37, 38]. Moreover, external validity of observational studies may be higher than for randomized controlled trials. Third, because of the study design, we cannot provide detailed explanations about the protective mechanisms of etomidate on long-term outcomes.
In the present study, the hypnotic used to facilitate intubation in critically ill patients was mainly etomidate to limit the risk of cardiovascular collapse that may occur after intubation . Propofol or pentobarbital represented 20% of the administered hypnotics (Table 2), mainly in the operating room for urgent surgery. The difficult intubation rate was high (near 10%), which is above the usual rate in the operating room but is similar to the rate reported in the few studies existing in this field [2, 5]. To facilitate intubation, almost all of the patients received a myorelaxant agent (Table 1), mostly succinylcholine, as recommended by our local protocol. Interestingly, the short-term life-threatening complications that occurred within 1 hour after intubation concerned 36% of the patients. This rate is similar to that in the literature [2, 4] and above the rate we reported after the implementation of a care bundle in nonselected critically ill patients . The discrepancy between the present study and our previous results  may be explained by the severity of the patients in the present study, all of them intubated with cardiovascular instability related to sepsis. In the multivariate analysis, the sole factor associated with short-term outcome was the administration, prior to intubation, of norepinephrine (Table 2). Norepinephrine administration before intubation may be protective by both limiting the risk of severe cardiovascular collapse following sympatholysis induced by the hypnotic and the detrimental effect of thoracic positive pressure on venous return. In our unit, norepinephrine prior to induction is suggested for diastolic blood pressure < 45 to 50 mmHg .
In the present study, we assessed the short-term life-threatening complication rate, but also the long-term effect of hypnotics on outcome. Patients intubated with etomidate were more likely to present CIRCI (Table 4) and needed a longer hydrocortisone treatment and a higher total amount of hydrocortisone. One bolus of etomidate impairs cortisol secretion [8, 9, 39, 40] by the inhibition, for at least 24 to 48 hours, of 11β-hydroxylase, the enzyme that converts 11β-deoxycortisol to cortisol in critically ill patients [8, 10, 21]. The higher rate of CIRCI when patients received etomidate may explain the higher cumulative dose of hydrocortisone because, in the present study, hydrocortisone was tapered and stopped according to the reversal of shock. CIRCI is associated with increased morbidity and mortality in septic shock patients [8, 13, 14, 22]. However, despite a higher rate of CIRCI, we showed that etomidate was a protective factor for mortality in both unmatched and matched cohorts (Figure 2).
Our study provides new data on the effect of etomidate in septic shock. In a post-hoc analysis of a multiple-center trial designed to evaluate the impact of hydrocortisone treatment in septic shock patients, the authors reported an increased death rate in patients that had been intubated with etomidate compared with other hypnotics . In contradiction, this increase was not statistically significant after adjustment in a multivariate analysis . Furthermore, Cuthbertson and colleagues showed that administration of etomidate was associated with increased mortality, but in only one of two multiple regression models . Despite higher severity of illness scores in patients intubated with etomidate compared with patients intubated with another hypnotic (Table 1), our study demonstrated a protective effect of etomidate on day-28 mortality using Cox regression. This effect was confirmed after matching (Figure 2).
The consequences of etomidate on long-term outcomes in the present study must be discussed in light of the co-administration of hydrocortisone. In the present study, hydrocortisone treatment was started within the first 12 hours after etomidate administration, earlier than in other studies . To date, studies have failed to demonstrate an improved outcome when supplementing etomidate treatment with corticosteroids [10, 22, 24] and hydrocortisone is not recommended in every patient presenting septic shock but is suggested in those refractory to fluid challenge and dependent on high-dose vasopressors . However, because the inhibition of cortisol synthesis due to etomidate is immediate, hydrocortisone must be administered immediately after an etomidate bolus to counter its effects on steroid synthesis . Evaluating the role of hydrocortisone in patients who received etomidate may thus be interesting. To explain the impact of etomidate, it has also been reported that ketamine - which was the main drug used in the non-etomidate cohort - may have an anti-inflammatory effect in experimental sepsis models [41, 42]. Whether this anti-inflammatory effect may exacerbate late sepsis-induced immunosuppression, however, is unknown.
We have reported that etomidate use for intubation in septic shock patients treated with hydrocortisone did not prevent short-term life-threatening complications following intubation despite its cardiovascular tolerance profile. Our study also suggests that patients co-treated with etomidate and hydrocortisone might not be associated with a worse outcome than another hypnotic used to facilitate intubation. Future randomized controlled studies should be performed to confirm this result and to evaluate early hydrocortisone treatment in septic shock patients who received etomidate.
In septic shock patients treated with hydrocortisone, despite its cardiovascular tolerance, etomidate was not associated with a decrease of life-threatening complications following intubation in comparison with other hypnotics.
Etomidate was associated with a longer period of shock and higher cumulative dose of hydrocortisone than patients intubated with another hypnotic.
Interestingly, patients treated with etomidate and hydrocortisone presented a lower risk of day-28 mortality, both in unmatched and matched cohorts and multivariate analysis.
critical illness-related corticosteroid insufficiency.
The authors are grateful to Patrick McSweeny for his technical support.
- Baillard C, Fosse JP, Sebbane M, Chanques G, Vincent F, Courouble P, Cohen Y, Eledjam JJ, Adnet F, Jaber S: Noninvasive ventilation improves preoxygenation before intubation of hypoxic patients. Am J Respir Crit Care Med 2006, 174: 171-177. 10.1164/rccm.200509-1507OCView ArticlePubMedGoogle Scholar
- Jaber S, Amraoui J, Lefrant JY, Arich C, Cohendy R, Landreau L, Calvet Y, Capdevila X, Mahamat A, Eledjam JJ: Clinical practice and risk factors for immediate complications of endotracheal intubation in the intensive care unit: a prospective, multiple-center study. Crit Care Med 2006, 34: 2355-2361. 10.1097/01.CCM.0000233879.58720.87View ArticlePubMedGoogle Scholar
- Petrini F, Accorsi A, Adrario E, Agro F, Amicucci G, Antonelli M, Azzeri F, Baroncini S, Bettelli G, Cafaggi C, Cattano D, Chinelli E, Corbanese U, Corso R, Della Puppa A, Di Filippo A, Facco E, Favaro R, Favero R, Frova G, Giunta F, Giurati G, Giusti F, Guarino A, Iannuzzi E, Ivani G, Mazzon D, Menarini M, Merli G, Mondello E, et al.: Recommendations for airway control and difficult airway management. Minerva Anestesiol 2005, 71: 617-657.PubMedGoogle Scholar
- Griesdale DE, Bosma TL, Kurth T, Isac G, Chittock DR: Complications of endotracheal intubation in the critically ill. Intensive Care Med 2008, 34: 1835-1842. 10.1007/s00134-008-1205-6View ArticlePubMedGoogle Scholar
- Jaber S, Jung B, Corne P, Sebbane M, Muller L, Chanques G, Verzilli D, Jonquet O, Eledjam JJ, Lefrant JY: An intervention to decrease complications related to endotracheal intubation in the intensive care unit: a prospective, multiple-center study. Intensive Care Med 2010, 36: 248-255. 10.1007/s00134-009-1717-8View ArticlePubMedGoogle Scholar
- Jabre P, Combes X, Lapostolle F, Dhaouadi M, Ricard-Hibon A, Vivien B, Bertrand L, Beltramini A, Gamand P, Albizzati S, Perdrizet D, Lebail G, Chollet-Xernard C, Maxime V, Brun-Buisson C, Lefrant JY, Bollaert PE, Megarbane B, Ricard JD, Anguel N, Vicaut E, Adnet F: Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009, 374: 293-300. 10.1016/S0140-6736(09)60949-1View ArticlePubMedGoogle Scholar
- Walz JM, Zayaruzny M, Heard SO: Airway management in critical illness. Chest 2007, 131: 608-620. 10.1378/chest.06-2120View ArticlePubMedGoogle Scholar
- Malerba G, Romano-Girard F, Cravoisy A, Dousset B, Nace L, Levy B, Bollaert PE: Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005, 31: 388-392. 10.1007/s00134-004-2550-8View ArticlePubMedGoogle Scholar
- Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D: Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984, 310: 1415-1421. 10.1056/NEJM198405313102202View ArticlePubMedGoogle Scholar
- Payen JF, Dupuis C, Trouve-Buisson T, Vinclair M, Broux C, Bouzat P, Genty C, Monneret D, Faure P, Chabre O, Bosson JL: Corticosteroid after etomidate in critically ill patients: a randomized controlled trial. Crit Care Med 2012, 40: 29-35. 10.1097/CCM.0b013e31822d7938View ArticlePubMedGoogle Scholar
- den Brinker M, Hokken-Koelega AC, Hazelzet JA, de Jong FH, Hop WC, Joosten KF: One single dose of etomidate negatively influences adrenocortical performance for at least 24 h in children with meningococcal sepsis. Intensive Care Med 2008, 34: 163-168. 10.1007/s00134-007-0836-3PubMed CentralView ArticlePubMedGoogle Scholar
- Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, Keh D, Briegel J, Beishuizen A, Dimopoulou I, Tsagarakis S, Singer M, Chrousos GP, Zaloga G, Bokhari F, Vogeser M: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008, 36: 1937-1949. 10.1097/CCM.0b013e31817603baView ArticlePubMedGoogle Scholar
- Annane D, Bellissant E: Prognostic value of cortisol response in septic shock. JAMA 2000, 284: 308-309. 10.1001/jama.284.3.308View ArticlePubMedGoogle Scholar
- de Jong MF, Beishuizen A, Spijkstra JJ, Groeneveld AB: Relative adrenal insufficiency as a predictor of disease severity, mortality, and beneficial effects of corticosteroid treatment in septic shock. Crit Care Med 2007, 35: 1896-1903. 10.1097/01.CCM.0000275387.51629.EDView ArticlePubMedGoogle Scholar
- Jung B, Nougaret S, Chanques G, Mercier G, Cisse M, Aufort S, Gallix B, Annane D, Jaber S: Absence of adrenal gland enlargement during septic shock predicts mortality: a computed tomography scan study of 239 patients. Anesthesiology 2011, 115: 334-343. 10.1097/ALN.0b013e318225cfd7View ArticlePubMedGoogle Scholar
- Annane D: ICU physicians should abandon the use of etomidate! Intensive Care Med 2005, 31: 325-326. 10.1007/s00134-005-2560-1View ArticlePubMedGoogle Scholar
- de Jong MF, Beishuizen A, Spijkstra JJ, Girbes AR, Groeneveld AB: Relative adrenal insufficiency: an identifiable entity in nonseptic critically ill patients? Clin Endocrinol (Oxf) 2007, 66: 732-739. 10.1111/j.1365-2265.2007.02814.xView ArticleGoogle Scholar
- Jackson WL Jr: Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?: a critical appraisal. Chest 2005, 127: 1031-1038. 10.1378/chest.127.3.1031View ArticlePubMedGoogle Scholar
- Albert SG, Ariyan S, Rather A: The effect of etomidate on adrenal function in critical illness: a systematic review. Intensive Care Med 2011, 37: 901-910. 10.1007/s00134-011-2160-1View ArticlePubMedGoogle Scholar
- Cuthbertson BH, Sprung CL, Annane D, Chevret S, Garfield M, Goodman S, Laterre PF, Vincent JL, Freivogel K, Reinhart K, Singer M, Payen D, Weiss YG: The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009, 35: 1868-1876. 10.1007/s00134-009-1603-4View ArticlePubMedGoogle Scholar
- Lipiner-Friedman D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, Briegel J, Keh D, Singer M, Moreno R, Bellissant E, Annane D: Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007, 35: 1012-1018. 10.1097/01.CCM.0000259465.92018.6EView ArticlePubMedGoogle Scholar
- Mohammad Z, Afessa B, Finkielman JD: The incidence of relative adrenal insufficiency in patients with septic shock after the administration of etomidate. Crit Care 2006, 10: R105. 10.1186/cc4979PubMed CentralView ArticlePubMedGoogle Scholar
- Dmello D, Taylor S, O'Brien J, Matuschak GM: Outcomes of etomidate in severe sepsis and septic shock. Chest 2010, 138: 1327-1332. 10.1378/chest.10-0790View ArticlePubMedGoogle Scholar
- Ray DC, McKeown DW: Effect of induction agent on vasopressor and steroid use, and outcome in patients with septic shock. Crit Care 2007, 11: R56. 10.1186/cc5916PubMed CentralView ArticlePubMedGoogle Scholar
- Riche FC, Boutron CM, Valleur P, Berton C, Laisne MJ, Launay JM, Chappuis P, Peynet J, Vicaut E, Payen D, Cholley BP: Adrenal response in patients with septic shock of abdominal origin: relationship to survival. Intensive Care Med 2007, 33: 1761-1766. 10.1007/s00134-007-0770-4View ArticlePubMedGoogle Scholar
- Nougaret S, Jung B, Aufort S, Chanques G, Jaber S, Gallix B: Adrenal gland volume measurement in septic shock and control patients: a pilot study. Eur Radiol 2010, 20: 2348-2357. 10.1007/s00330-010-1804-9View ArticlePubMedGoogle Scholar
- Annane D: Corticosteroids for severe sepsis: an evidence-based guide for physicians. Annals Intensive Care 2011, 1: 1-7. 10.1186/2110-5820-1-1View ArticleGoogle Scholar
- Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358: 111-124. 10.1056/NEJMoa071366View ArticlePubMedGoogle Scholar
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008, 61: 344-349. 10.1016/j.jclinepi.2007.11.008View ArticlePubMedGoogle Scholar
- Vinclair M, Broux C, Faure P, Brun J, Genty C, Jacquot C, Chabre O, Payen JF: Duration of adrenal inhibition following a single dose of etomidate in critically ill patients. Intensive Care Med 2008, 34: 714-719. 10.1007/s00134-007-0970-yView ArticlePubMedGoogle Scholar
- Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Servansky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36: 296-327. 10.1097/01.CCM.0000298158.12101.41View ArticlePubMedGoogle Scholar
- Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655. 10.1378/chest.101.6.1644View ArticlePubMedGoogle Scholar
- Gilbert EH, Lowenstein SR, Koziol-McLain J, Barta DC, Steiner J: Chart reviews in emergency medicine research: where are the methods? Ann Emerg Med 1996, 27: 305-308. 10.1016/S0196-0644(96)70264-0View ArticlePubMedGoogle Scholar
- Gayat E, Pirracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R: Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med 2011, 36: 1993-2003.View ArticleGoogle Scholar
- Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270: 2957-2963. 10.1001/jama.1993.03510240069035View ArticlePubMedGoogle Scholar
- Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26: 1793-1800. 10.1097/00003246-199811000-00016View ArticlePubMedGoogle Scholar
- Fernandez R, Tizon AI, Gonzalez J, Monedero P, Garcia-Sanchez M, de-la-Torre MV, Ibanez P, Frutos F, del-Nogal F, Gomez MJ, Marcos A, Hernandez G: Intensive care unit discharge to the ward with a tracheostomy cannula as a risk factor for mortality: a prospective, multicenter propensity analysis. Crit Care Med 2011, 39: 2240-2245. 10.1097/CCM.0b013e3182227533View ArticlePubMedGoogle Scholar
- Suarez D, Haro JM, Novick D, Ochoa S: Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies. J Clin Epidemiol 2008, 61: 525-530. 10.1016/j.jclinepi.2007.11.007View ArticlePubMedGoogle Scholar
- de Jong FH, Mallios C, Jansen C, Scheck PA, Lamberts SW: Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984, 59: 1143-1147. 10.1210/jcem-59-6-1143View ArticlePubMedGoogle Scholar
- Hildreth AN, Mejia VA, Maxwell RA, Smith PW, Dart BW, Barker DE: Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. J Trauma 2008, 65: 573-579. 10.1097/TA.0b013e31818255e8View ArticlePubMedGoogle Scholar
- Chang HC, Lin KH, Tai YT, Chen JT, Chen RM: Lipoteichoic acid-induced TNF-alpha and IL-6 gene expressions and oxidative stress production in macrophages are suppressed by ketamine through downregulating Toll-like receptor 2-mediated activation oF ERK1/2 and NFκB. Shock 2010, 33: 485-492.View ArticlePubMedGoogle Scholar
- Yu M, Shao D, Liu J, Zhu J, Zhang Z, Xu J: Effects of ketamine on levels of cytokines, NF-κB and TLRs in rat intestine during CLP-induced sepsis. Int Immunopharmacol 2007, 7: 1076-1082. 10.1016/j.intimp.2007.04.003View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.